Jennifer K Saucier-Sawyer
Overview
Explore the profile of Jennifer K Saucier-Sawyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
618
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vohidov F, Andersen J, Economides K, Shipitsin M, Burenkova O, Ackley J, et al.
J Am Chem Soc
. 2021 Mar;
143(12):4714-4724.
PMID: 33739832
Prodrugs engineered for preferential activation in diseased versus normal tissues offer immense potential to improve the therapeutic indexes (TIs) of preclinical and clinical-stage active pharmaceutical ingredients that either cannot be...
2.
Golder M, Liu J, Andersen J, Shipitsin M, Vohidov F, Nguyen H, et al.
Nat Biomed Eng
. 2019 Apr;
2(9):707.
PMID: 31015683
In the version of this Article originally published, the author Peter Blume-Jensen was not denoted as a corresponding author; this has now been amended and the author's email address has...
3.
Golder M, Liu J, Andersen J, Shipitsin M, Vohidov F, Nguyen H, et al.
Nat Biomed Eng
. 2019 Mar;
2(11):822-830.
PMID: 30918745
At present there are no drugs for the treatment of chronic liver fibrosis that have been approved by the Food and Drug administration of the United States. Telmisartan, a small-molecule...
4.
Gaudin A, Song E, King A, Saucier-Sawyer J, Bindra R, Desmaele D, et al.
Biomaterials
. 2016 Aug;
105:136-144.
PMID: 27521616
New treatments for glioblastoma multiforme (GBM) are desperately needed, as GBM prognosis remains poor, mainly due to treatment resistance, poor distribution of therapeutics in the tumor tissue, and fast metabolism...
5.
Saucier-Sawyer J, Seo Y, Gaudin A, Quijano E, Song E, Sawyer A, et al.
J Control Release
. 2016 Apr;
232:103-12.
PMID: 27063424
Glioblastoma multiforme (GBM) is a fatal brain tumor characterized by infiltration beyond the margins of the main tumor mass and local recurrence after surgery. The blood-brain barrier (BBB) poses the...
6.
Saucier-Sawyer J, Deng Y, Seo Y, Cheng C, Zhang J, Quijano E, et al.
J Drug Target
. 2015 Oct;
23(7-8):736-49.
PMID: 26453169
Delivery of therapeutic agents to the central nervous system is a significant challenge, hindering progress in the treatment of diseases such as glioblastoma. Due to the presence of the blood-brain...
7.
Cheng C, Tietjen G, Saucier-Sawyer J, Saltzman W
Nat Rev Drug Discov
. 2015 Jan;
14(4):239-47.
PMID: 25598505
The primary goal of nanomedicine is to improve clinical outcomes. To this end, targeted nanoparticles are engineered to reduce non-productive distribution while improving diagnostic and therapeutic efficacy. Paradoxically, as this...
8.
Sawyer A, Tian W, Saucier-Sawyer J, Rizk P, Saltzman W, Bellamkonda R, et al.
Biomaterials
. 2014 Jun;
35(25):6698-706.
PMID: 24881026
Intracranial implants elicit neurodegeneration via the foreign body response (FBR) that includes BBB leakage, macrophage/microglia accumulation, and reactive astrogliosis, in addition to neuronal degradation that limit their useful lifespan. Previously,...
9.
Deng Y, Saucier-Sawyer J, Hoimes C, Zhang J, Seo Y, Andrejecsk J, et al.
Biomaterials
. 2014 May;
35(24):6595-602.
PMID: 24816286
A key attribute for nanoparticles (NPs) that are used in medicine is the ability to avoid rapid uptake by phagocytic cells in the liver and other tissues. Poly(ethylene glycol) (PEG)...
10.
Prasad S, Cody V, Saucier-Sawyer J, Fadel T, Edelson R, Birchall M, et al.
Pharm Res
. 2012 Jul;
29(9):2565-77.
PMID: 22798259
Purpose: In order to investigate Poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NP) as potential vehicles for efficient tumor antigen (TA) delivery to dendritic cells (DC), this study aimed to optimize encapsulation/release...